NCT04912284

Brief Summary

Vaccine hesitancy is defined by the WHO's Strategic Advisory Group of Experts on Immunization as a 'delay in acceptance or refusal of vaccination despite availability of vaccination services'. This varies in form and intensity based on when and where it occurs and what vaccine is involved. Several prophylactic vaccines against COVID-19 are currently available. As the world is beginning the roll-out the first approved vaccines, little is known about people's potential acceptance of a COVID-19 vaccine in most of the African countries. ACHES (African COVID -19Vaccine Hesitancy) is an observational study aimed at measuring COVID-19 vaccine hesitancy in five west African countries and exploring causes behind the hesitancy with the main objective of informing guidelines for the proficient roll-out of the vaccines in the region.

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4,977

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2021

Shorter than P25 for all trials

Geographic Reach
5 countries

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 5, 2021

Completed
26 days until next milestone

First Submitted

Initial submission to the registry

May 31, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 3, 2021

Completed
3 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 6, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 6, 2021

Completed
Last Updated

June 21, 2021

Status Verified

June 1, 2021

Enrollment Period

1 month

First QC Date

May 31, 2021

Last Update Submit

June 16, 2021

Conditions

Covid19

Keywords

Vaccine hesitancyVaccinesWest Africa

Outcome Measures

Primary Outcomes (1)

  • Frequency of vaccine hesitancy

    To describe and compare levels of COVID-19 vaccine hesitancy among the general population and health care workers in rural and urban settings across different African countries

    1 month

Secondary Outcomes (1)

  • Factors influencing vaccine hesitancy

    1 month

Study Arms (2)

General population

Questionnaire administered to adult population

Health care workers

Questionnaire administered to adult health care workers

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The general population will be selected in the capital and a rural area (around the capital) from each country. Approximately 5 clusters per area will be considered. The interviews will be house hold based. Health workers will be interviewed in facilities located in the study area and selected by the local study coordinator. Only people who have direct contact with patients will be considered for the analysis. To select study participants, staff lists including social workers from each facility will be used to randomly select people to be interviewed.

You may qualify if:

  • General population
  • Be at least 18 years of age, be willing and able to provide written informed consent AND
  • Health professionals
  • To be health professionals working in health care institutions at all levels of care for the Ministry of Health (MoH)
  • freely consent to participate in the study

You may not qualify if:

  • All minors (\<18)
  • In Senegal
  • All those already vaccinated or being offered a vaccination for COVID-19 and refused and/or delayed the vaccination

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Henri Gautier Ouedragogo

Ouagadougou, 7192, Burkina Faso

Location

Alpha Mahmoud Barry

Conakry, Guinea

Location

Seydou Doumbia

Bamako, Mali

Location

Sylvain Faye

Dakar, Senegal

Location

Abdul Mbawah

Freetown, Sierra Leone

Location

Related Publications (8)

  • MacDonald NE; SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015 Aug 14;33(34):4161-4. doi: 10.1016/j.vaccine.2015.04.036. Epub 2015 Apr 17.

    PMID: 25896383BACKGROUND

  • Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, Kimball S, El-Mohandes A. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021 Feb;27(2):225-228. doi: 10.1038/s41591-020-1124-9. Epub 2020 Oct 20.

    PMID: 33082575BACKGROUND

  • Schwarzinger M, Watson V, Arwidson P, Alla F, Luchini S. COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics. Lancet Public Health. 2021 Apr;6(4):e210-e221. doi: 10.1016/S2468-2667(21)00012-8. Epub 2021 Feb 6.

    PMID: 33556325BACKGROUND

  • Samarasekera U. Feelings towards COVID-19 vaccination in Africa. Lancet Infect Dis. 2021 Mar;21(3):324. doi: 10.1016/S1473-3099(21)00082-7. No abstract available.

    PMID: 33639125BACKGROUND

  • Dada S, McKay G, Mateus A, Lees S. Lessons learned from engaging communities for Ebola vaccine trials in Sierra Leone: reciprocity, relatability, relationships and respect (the four R's). BMC Public Health. 2019 Dec 11;19(1):1665. doi: 10.1186/s12889-019-7978-4.

    PMID: 31829223BACKGROUND

  • Larson HJ, Jarrett C, Schulz WS, Chaudhuri M, Zhou Y, Dube E, Schuster M, MacDonald NE, Wilson R; SAGE Working Group on Vaccine Hesitancy. Measuring vaccine hesitancy: The development of a survey tool. Vaccine. 2015 Aug 14;33(34):4165-75. doi: 10.1016/j.vaccine.2015.04.037. Epub 2015 Apr 18.

    PMID: 25896384BACKGROUND

  • Di Meglio F, Lhomme E, Ouedraogo HG, Barry AM, Doumbia S, Faye SL, Mbawah AK, Sagna T, Tounkara M, Strauss R, Doumbia CO, Diouf S, Cisse K, May J, Puradiredja DI, Fusco D. Variations in COVID-19 vaccine hesitancy over time: a serial cross-sectional study in five West African countries. BMJ Open. 2024 Nov 7;14(11):e083766. doi: 10.1136/bmjopen-2023-083766.

    PMID: 39510778DERIVED

  • Faye SLB, Krumkamp R, Doumbia S, Tounkara M, Strauss R, Ouedraogo HG, Sagna T, Barry AM, Mbawah AK, Doumbia CO, Diouf S, Cisse K, Harding M, Donven P, May J, Puradiredja DI, Fusco D; ACHES consortium. Factors influencing hesitancy towards adult and child COVID-19 vaccines in rural and urban West Africa: a cross-sectional study. BMJ Open. 2022 Apr 13;12(4):e059138. doi: 10.1136/bmjopen-2021-059138.

    PMID: 35418436DERIVED

MeSH Terms

Conditions

COVID-19Vaccination Hesitancy

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesVaccination RefusalTreatment RefusalTreatment Adherence and ComplianceHealth BehaviorBehavior

Study Officials

  • Daniela Fusco, PhD

    Bernhard Nocht Institute for Tropical Medicine

    PRINCIPAL INVESTIGATOR

  • Henri Gautier Ouedraogo, Prof

    University of Ouagadougu

    PRINCIPAL INVESTIGATOR

  • Alpha Mahmoud Barry, Dr

    Santé Plus

    PRINCIPAL INVESTIGATOR

  • Seydou Doumbia, Prof

    University of Bamako

    PRINCIPAL INVESTIGATOR

  • Sylvain Faye, Prof

    Cheikh Anta Diop University, Senegal

    PRINCIPAL INVESTIGATOR

  • Abdullah Mbawah, Dr

    University of Freetown

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
ECOLOGIC OR COMMUNITY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 31, 2021

First Posted

June 3, 2021

Study Start

May 5, 2021

Primary Completion

June 6, 2021

Study Completion

June 6, 2021

Last Updated

June 21, 2021

Record last verified: 2021-06

Locations

BU(1)SE(1)SI(1)MA(1)GU(1)